Faslodex: Phase III

AZN said that in a total of 851 post-menopausal women with progressed or recurrent advanced breast cancer in 2 Phase III trials, a once-monthly injection of Faslodex was as effective as the company's marketed Arimidex anastrozole oral aromatase inhibitor in terms of time to progression and response rate. In the North American Phase III study, time to progression, the primary end point, was 5.4 months in the Faslodex group and 3.4 months in the Arimidex group; in the European trial it was 5.5 months and 5.2 months, respectively. The median duration of response in the North American trial for Faslodex patients was 19.3 months compared to 10.5 months for the Arimidex group; in the European trial it was 434 and 425 days, respectively. ...